Atai Life Sciences N.V.

NasdaqGM:ATAI Stock Report

Market Cap: US$331.5m

Atai Life Sciences Future Growth

Future criteria checks 2/6

Atai Life Sciences is forecast to grow earnings and revenue by 40.1% and 70.5% per annum respectively. EPS is expected to grow by 47.5% per annum. Return on equity is forecast to be -45.6% in 3 years.

Key information

40.1%

Earnings growth rate

47.5%

EPS growth rate

Pharmaceuticals earnings growth22.9%
Revenue growth rate70.5%
Future return on equity-45.6%
Analyst coverage

Good

Last updated03 Apr 2024

Recent future growth updates

Recent updates

Is Atai Life Sciences (NASDAQ:ATAI) Using Debt Sensibly?

Mar 02
Is Atai Life Sciences (NASDAQ:ATAI) Using Debt Sensibly?

atai Life Sciences achieves positive results in phase 1 trial of kratom-derived drug

Oct 12

Atai Life Sciences: Decentralized Drug Discovery Platform

Oct 06

ATAI Life Sciences GAAP EPS of -$0.24 misses by $0.01

Aug 15

We're Hopeful That Atai Life Sciences (NASDAQ:ATAI) Will Use Its Cash Wisely

Aug 07
We're Hopeful That Atai Life Sciences (NASDAQ:ATAI) Will Use Its Cash Wisely

Atai Life Sciences: Leading But Early Stage Psychedelic Therapeutics Developer

Jul 07

atai Life Sciences company Kures Therapeutics appoints Dr. Chad Beyer as CEO

Jun 30

Atai Life Sciences N.V.: A First Take

Jun 02

Atai Life Sciences And The Future Of Psychedelics For Mental Health

May 27

We're Hopeful That Atai Life Sciences (NASDAQ:ATAI) Will Use Its Cash Wisely

Apr 22
We're Hopeful That Atai Life Sciences (NASDAQ:ATAI) Will Use Its Cash Wisely

Earnings and Revenue Growth Forecasts

NasdaqGM:ATAI - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202637-120-144-1415
12/31/20250-151-112-1226
12/31/20240-133-101-976
12/31/20230-40-85-84N/A
9/30/20230-67-93-93N/A
6/30/20230-145-104-102N/A
3/31/20230-149-103-102N/A
12/31/20220-152-105-104N/A
9/30/20220-196-97-94N/A
6/30/20221-194-96-95N/A
3/31/20220-205-73-71N/A
12/31/202120-168-65-63N/A
9/30/202120-166-50-49N/A
6/30/202120-218-27-26N/A
3/31/202120-185-34-33N/A
12/31/2020N/A-170-21-21N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ATAI is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ATAI is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ATAI is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ATAI's revenue (70.5% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: ATAI's revenue (70.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ATAI is forecast to be unprofitable in 3 years.


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.